Insider Selling: Bausch Health Companies Inc (NYSE:BHC) EVP Sells 3,968 Shares of Stock

Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann sold 3,968 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $24.81, for a total transaction of $98,446.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of BHC opened at $22.91 on Thursday. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. The stock’s 50 day simple moving average is $23.16. Bausch Health Companies Inc has a 1-year low of $17.20 and a 1-year high of $28.45. The stock has a market cap of $8.15 billion, a PE ratio of 5.57, a price-to-earnings-growth ratio of 0.52 and a beta of 0.78.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.14. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The business had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the company posted $0.89 EPS. The company’s revenue was up 1.1% on a year-over-year basis. On average, equities analysts expect that Bausch Health Companies Inc will post 4.19 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. FIL Ltd increased its stake in shares of Bausch Health Companies by 69.6% during the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after purchasing an additional 4,327,851 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Bausch Health Companies by 28.2% during the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after purchasing an additional 815,311 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of Bausch Health Companies by 89.1% during the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after purchasing an additional 1,696,400 shares in the last quarter. Norges Bank acquired a new stake in Bausch Health Companies during the fourth quarter worth approximately $59,054,000. Finally, Clearbridge Investments LLC boosted its position in Bausch Health Companies by 0.5% during the first quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock worth $71,563,000 after acquiring an additional 14,610 shares during the last quarter. 53.66% of the stock is owned by institutional investors and hedge funds.

BHC has been the subject of a number of research analyst reports. Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Tuesday, June 11th. Mizuho set a $45.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald set a $32.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Friday, May 31st. JPMorgan Chase & Co. increased their target price on shares of Vermilion Energy from C$42.00 to C$43.00 in a report on Monday, May 13th. Finally, Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a report on Monday. Three analysts have rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $27.65.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Read More: Conference Calls and Individual Investors

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.